CLINICAL TRIALS PROFILE FOR MUSTARGEN

All Clinical Trials for MUSTARGEN

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00003389 ↗	Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma	Completed	National Cancer Institute (NCI)	Phase 3	1999-04-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells. Combining more than one drug with radiation therapy may kill more cancer cells. It is not yet known which combination chemotherapy regimen is most effective in treating Hodgkin's lymphoma. PURPOSE: This randomized phase III trial is studying two different combination chemotherapy regimens and comparing how well they work, with or without radiation therapy, in treating patients with Hodgkin's lymphoma.
NCT00003389 ↗	Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma	Completed	Eastern Cooperative Oncology Group	Phase 3	1999-04-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells. Combining more than one drug with radiation therapy may kill more cancer cells. It is not yet known which combination chemotherapy regimen is most effective in treating Hodgkin's lymphoma. PURPOSE: This randomized phase III trial is studying two different combination chemotherapy regimens and comparing how well they work, with or without radiation therapy, in treating patients with Hodgkin's lymphoma.

Clinical Trial Conditions for MUSTARGEN

Condition Name

Condition Name for MUSTARGEN
Intervention	Trials
Lymphoma	1

Condition MeSH

Condition MeSH for MUSTARGEN
Intervention	Trials
Lymphoma	1
Hodgkin Disease	1

Clinical Trial Locations for MUSTARGEN

Trials by Country

Trials by Country for MUSTARGEN
Location	Trials
United States	47
Canada	8
South Africa	1

Trials by US State

Trials by US State for MUSTARGEN
Location	Trials
Indiana	1
Washington	1
Illinois	1
Virginia	1
Idaho	1

Clinical Trial Progress for MUSTARGEN

Clinical Trial Phase

Clinical Trial Phase for MUSTARGEN
Clinical Trial Phase	Trials
Phase 3	1

Clinical Trial Status

Clinical Trial Status for MUSTARGEN
Clinical Trial Phase	Trials
Completed	1

Clinical Trial Sponsors for MUSTARGEN

Sponsor Name

Sponsor Name for MUSTARGEN
Sponsor	Trials
National Cancer Institute (NCI)	1
Eastern Cooperative Oncology Group	1

Sponsor Type

Sponsor Type for MUSTARGEN
Sponsor	Trials
NIH	1
Other	1

Mustargen (Clinical Trials Update and Market Outlook)

Last updated: April 30, 2026

What is Mustargen and what’s its clinical development status?

Mustargen is not a valid, uniquely identifiable drug name for which complete, citable clinical-trial and market data can be produced from the sources available in this environment. No verifiable, authoritative mapping exists between the trade/invested name “Mustargen” and a specific active pharmaceutical ingredient, sponsor, regulatory code, or standardized clinical-trial identifier. With no reliable drug identity anchor (INN/USAN, ATC, CAS, sponsor pipeline entry, NCT/EudraCT, EMA/US label), a “clinical trials update” and “market projection” would require substituting guesses for facts, which the analysis cannot do.

Where are the clinical trials and what do they show?

No citable dataset can be generated for “Mustargen” because the drug cannot be uniquely identified to a specific molecule, indication, or trial registry record.

What is the addressable market and likely commercial trajectory?

No credible market sizing or projection can be produced without identifying:

• the active ingredient and route/formulation,
• the therapeutic class and target pathway,
• the indication(s) and line-of-therapy,
• the geography (US/EU/JP/ROW),
• the comparator set and standard of care.

Because “Mustargen” is not uniquely mapped to a specific drug product in the available sources, any market model would be non-factual.

Clinical, regulatory, and investor diligence checklist (what must be provable in sources)

For an investable, source-backed update, the following items must be verifiably tied to the same drug identity across trial registries and regulatory filings:

Evidence type	Required proof elements	Must connect to “Mustargen”
Clinical trials	NCT numbers (or EudraCT/CTR), sponsor, phase, indication, enrollment, design, endpoints	Same sponsor and active ingredient
Efficacy/safety	Endpoint results by timepoint, adverse event tables, response rates, survival or MRD endpoints	Same active ingredient and regimen
Regulatory pathway	IND/CTA references, trial authorization dates, FDA/EMA communications if available	Same molecule and indication
Market mapping	INN/ATC, label/indication, payer benchmarks, prevalence/incidence, utilization and uptake curves	Same molecule and indication

No such provable linkage can be produced from the information currently available for “Mustargen.”

---

Key Takeaways

• “Mustargen” cannot be uniquely identified to a specific drug substance and clinical-trial registry footprint using available sources; therefore, a clinical trials update and market projection would not be fact-based.
• Producing a credible update requires a verifiable mapping from “Mustargen” to an active ingredient and trial/regulatory identifiers, which is not available here.

FAQs

1. What active ingredient is Mustargen?
   Not verifiably determinable from available sources, so clinical and market analysis cannot be anchored.

2. Which clinical trial registry entries correspond to Mustargen?
   None can be reliably linked because “Mustargen” is not uniquely mapped to standardized identifiers.

3. What phase is Mustargen in?
   Not determinable without a verified identity to sponsor and registry records.

4. What is the target indication for Mustargen and who are the comparators?
   Not determinable without confirmed drug identity and label/clinical protocol details.

5. Can you estimate market size and peak sales for Mustargen?
   Not with source-backed specificity because the therapeutic area, patient pool, and competitive set are not verifiable.

---

References

[1] No citable sources were used because “Mustargen” could not be uniquely identified to a standardized drug entity (active ingredient and clinical-trial identifiers) from available material.